GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review

Date: May 2, 2017
Pages: 104
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: G9753EE904AEN
Leaflet:

Download PDF Leaflet

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review
GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of respiratory, cancer, cardiovascular, HIV and infectious diseases, respiratory, immuno-inflammation and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and respiratory diseases. GSK’s vaccine portfolio cover various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups. GSK is headquartered in Brentford, Middlesex, the UK.

GlaxoSmithKline Plc Key Recent Developments

Apr 26,2017: GSK delivers another quarter of continued progress
Mar 22,2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis
Feb 16,2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms
Feb 08,2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016
Jan 19,2017: Abbas Hussain to leave GSK

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

GlaxoSmithKline Plc - Key Facts
GlaxoSmithKline Plc - Key Employees
GlaxoSmithKline Plc - Key Employee Biographies
GlaxoSmithKline Plc - Major Products and Services
GlaxoSmithKline Plc - Pharmaceutical Pipeline Products Data
GlaxoSmithKline Plc, Pipeline Products by Therapy Area
GlaxoSmithKline Plc, Pipeline Products by Development Phase
GlaxoSmithKline Plc - History
GlaxoSmithKline Plc - Company Statement
GlaxoSmithKline Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

GlaxoSmithKline Plc - Business Description
GlaxoSmithKline Plc - Corporate Strategy
GlaxoSmithKline Plc - SWOT Analysis
SWOT Analysis - Overview
GlaxoSmithKline Plc - Strengths
GlaxoSmithKline Plc - Weaknesses
GlaxoSmithKline Plc - Opportunities
GlaxoSmithKline Plc - Threats
GlaxoSmithKline Plc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES

GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
GlaxoSmithKline Plc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 26, 2017: GSK delivers another quarter of continued progress
Mar 22, 2017: U.K. Biobank, Regeneron and GSK Announce Largest Gene Sequencing Initiative on World's Most Detailed Health Database to Improve Drug Discovery and Disease Diagnosis
Feb 16, 2017: GSK and EMBL have signed an agreement to enhance understanding of disease and drug mechanisms
Feb 08, 2017: GlaxoSmithKline: Results announcement for the fourth quarter 2016
Jan 19, 2017: Abbas Hussain to leave GSK
Jan 19, 2017: Luke Miels appointed President, Global Pharmaceuticals, GSK
Dec 19, 2016: GSK announces Board changes
Oct 26, 2016: GlaxoSmithKline: Results Announcement for the third quarter 2016
Oct 06, 2016: CRT and University of Manchester receive success payment from GlaxoSmithKline for cancer epigenetics research collaboration
Sep 29, 2016: GlaxoSmithKline appoints Brian McNamara as CEO of GSK Consumer Healthcare

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

GlaxoSmithKline Plc, Key Facts
GlaxoSmithKline Plc, Key Employees
GlaxoSmithKline Plc, Key Employee Biographies
GlaxoSmithKline Plc, Major Products and Services
GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area
GlaxoSmithKline Plc, Number of Pipeline Products by Therapy Area (Cont.1)
GlaxoSmithKline Plc, Number of Pipeline Products by Development Stage
GlaxoSmithKline Plc, History
GlaxoSmithKline Plc, Other Locations
GlaxoSmithKline Plc, Subsidiaries
GlaxoSmithKline Plc, Joint Venture
GlaxoSmithKline Plc, Key Competitors
GlaxoSmithKline Plc, Ratios based on current share price
GlaxoSmithKline Plc, Annual Ratios
GlaxoSmithKline Plc, Annual Ratios (Cont.1)
GlaxoSmithKline Plc, Annual Ratios (Cont.2)
GlaxoSmithKline Plc, Interim Ratios
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
GlaxoSmithKline Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

GlaxoSmithKline Plc, Pipeline Products by Therapy Area
GlaxoSmithKline Plc, Pipeline Products by Development Phase
GlaxoSmithKline Plc, Performance Chart (2012 - 2016)
GlaxoSmithKline Plc, Ratio Charts
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
GlaxoSmithKline Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017

COMPANIES MENTIONED

Sophiris Bio Inc
Sanofi
Pfizer Inc
Oragenics Inc
Novartis AG
NewLink Genetics Corp
Napp Pharmaceuticals Ltd
Merck & Co Inc
F. Hoffmann-La Roche Ltd
Eli Lilly and Company
Cascadian Therapeutics Inc
Cardiome Pharma Corp
Bristol-Myers Squibb Company
Biofarm SA
AstraZeneca Plc
Aquinox Pharmaceuticals Inc
Amgen Inc
Skip to top


Ask Your Question

GlaxoSmithKline Plc (GSK) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: